We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In the wake of the outbreak of the COVID-19, the globally cumulative infected population has capped 100 million, which poses a huge impact on human activities.
AKL Research & Development (AKLRD) and Nordic Bioscience Clinical Development, announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA).